- CA$23.02m
- CA$24.39m
- CA$35.52m
- 40
- 92
- 53
- 64
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 13.67 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.62 | ||
Price to Tang. Book | 0.67 | ||
Price to Free Cashflow | 6.75 | ||
Price to Sales | 0.56 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -9.7% | ||
Return on Equity | -14.15% | ||
Operating Margin | -11.05% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | n/a | 9.39 | 22.61 | 35.52 | 41 | 47.7 | 109.3% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Rubicon Organics Inc. is a Canada-based company that is engaged in the production and sale of cannabis products. The Company, through its subsidiary, Rubicon Holdings Corp, is a licensed producer. The Company is engaged in cultivating, processing and selling organic certified cannabis products, which it sells under its owned and licensed brands. The Company's brands portfolio includes Simply Bare Organic, 1964 Supply Co., Homestead Cannabis Supply, Lab Theory and Wildflower. The Company owns and operates a fully licensed approximately 125,000 square foot high-tech greenhouse located on an approximately 20 acres property in Delta, British Columbia (the Delta Facility). The Delta Facility utilizes cold cure processing rooms and follows Good Production Practices (GPP) for processing dried flower, performing solvent-less extraction and packaging finished goods.
Directors
- Bryan Disher NEC (64)
- Tim Roberts PRE (43)
- Jesse Mcconnell CEO (43)
- Margaret Brodie CFO (42)
- Peter Doig CSO (42)
- Julie Lassonde DRC (49)
- David Donnan IND (65)
- John Pigott IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 15th, 2015
- Public Since
- October 10th, 2018
- No. of Employees
- 165
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 56,141,661
- Address
- 505 - 744 West Hastings Street, VANCOUVER, V6C 1A5
- Web
- https://rubiconorganics.com
- Phone
- +1 6048493733
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ROMJ
Q4 2023 Rubicon Organics Inc Earnings Call
Q1 2024 Rubicon Organics Inc Earnings Release
Q2 2024 Rubicon Organics Inc Earnings Release
Rubicon Organics Inc Annual Shareholders Meeting
Similar to ROMJ
ARCpoint
TSX Venture Exchange
Cannara Biotech
TSX Venture Exchange
Element Lifestyle Retirement
TSX Venture Exchange
Hempshire
TSX Venture Exchange
Jack Nathan Medical
TSX Venture Exchange
FAQ
As of Today at 18:18 UTC, shares in Rubicon Organics are trading at CA$0.41. This share price information is delayed by 15 minutes.
Shares in Rubicon Organics last closed at CA$0.41 and the price had moved by -30.65% over the past 365 days. In terms of relative price strength the Rubicon Organics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -38.48% over the past year.
The overall consensus recommendation for Rubicon Organics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Rubicon Organics does not currently pay a dividend.
Rubicon Organics does not currently pay a dividend.
Rubicon Organics does not currently pay a dividend.
To buy shares in Rubicon Organics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.41, shares in Rubicon Organics had a market capitalisation of CA$23.02m.
Here are the trading details for Rubicon Organics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ROMJ
Based on an overall assessment of its quality, value and momentum Rubicon Organics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rubicon Organics is CA$1.40. That is 241.46% above the last closing price of CA$0.41.
Analysts covering Rubicon Organics currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rubicon Organics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -20.96%.
As of the last closing price of CA$0.41, shares in Rubicon Organics were trading -12.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rubicon Organics PE ratio based on its reported earnings over the past 12 months is 13.67. The shares last closed at CA$0.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rubicon Organics' management team is headed by:
- Bryan Disher - NEC
- Tim Roberts - PRE
- Jesse Mcconnell - CEO
- Margaret Brodie - CFO
- Peter Doig - CSO
- Julie Lassonde - DRC
- David Donnan - IND
- John Pigott - IND